Have a feature idea you'd love to see implemented?
Let us know!
AMRX Amneal Pharmaceuticals Inc
Price (delayed)
$8.32
Market cap
$2.58B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.86
Enterprise value
$5.14B
Amneal Pharmaceuticals, Inc., headquartered in Bridgewater, NJ, is a fully-integrated pharmaceutical company focused on the development, manufacturing and distribution of generic and specialty drug products. The Company has operations in
Highlights
AMRX's revenue is up by 12% year-on-year and by 3.2% since the previous quarter
The company's gross profit rose by 12% YoY and by 4.1% QoQ
AMRX's quick ratio is down by 27% YoY but it is up by 2.7% from the previous quarter
Amneal Pharmaceuticals's equity has shrunk by 128% YoY and by 63% QoQ
AMRX's EPS is down by 8% since the previous quarter
Key stats
What are the main financial stats of AMRX
Market
Valuations
Earnings
Shares outstanding
309.84M
Market cap
$2.58B
Enterprise value
$5.14B
Price to book (P/B)
N/A
Price to sales (P/S)
0.96
EV/EBIT
53.95
EV/EBITDA
15.96
EV/Sales
1.92
Revenue
$2.68B
EBIT
$95.35M
EBITDA
$322.34M
Free cash flow
$263.18M
Per share
Balance sheet
Liquidity
EPS
-$0.86
Free cash flow per share
$0.85
Book value per share
-$0.3
Revenue per share
$8.66
TBVPS
$6.73
Total assets
$3.46B
Total liabilities
$3.55B
Debt
$2.64B
Equity
-$93.43M
Working capital
$418.09M
Debt to equity
-28.31
Current ratio
1.38
Quick ratio
0.76
Net debt/EBITDA
7.96
Margins
Efficiency
Dividend
EBITDA margin
12%
Gross margin
35.3%
Net margin
-6.9%
Operating margin
6.5%
Return on assets
-5.3%
Return on equity
N/A
Return on invested capital
2.6%
Return on capital employed
4%
Return on sales
3.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AMRX stock price
How has the Amneal Pharmaceuticals stock price performed over time
Intraday
-1.07%
1 week
-7.56%
1 month
-1.77%
1 year
86.13%
YTD
37.07%
QTD
0%
Financial performance
How have Amneal Pharmaceuticals's revenue and profit performed over time
Revenue
$2.68B
Gross profit
$947.39M
Operating income
$173.09M
Net income
-$184.45M
Gross margin
35.3%
Net margin
-6.9%
The operating margin has declined by 32% year-on-year but it is up by 3.2% since the previous quarter
The company's operating income fell by 24% YoY but it rose by 5% QoQ
AMRX's revenue is up by 12% year-on-year and by 3.2% since the previous quarter
The company's gross profit rose by 12% YoY and by 4.1% QoQ
Growth
What is Amneal Pharmaceuticals's growth rate over time
Valuation
What is Amneal Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
0.96
EV/EBIT
53.95
EV/EBITDA
15.96
EV/Sales
1.92
AMRX's EPS is down by 8% since the previous quarter
Amneal Pharmaceuticals's equity has shrunk by 128% YoY and by 63% QoQ
The price to sales (P/S) is 143% higher than the 5-year quarterly average of 0.4 and 39% higher than the last 4 quarters average of 0.7
AMRX's revenue is up by 12% year-on-year and by 3.2% since the previous quarter
Efficiency
How efficient is Amneal Pharmaceuticals business performance
AMRX's ROS has dropped by 58% year-on-year but it is up by 9% since the previous quarter
AMRX's ROIC is down by 49% YoY but it is up by 18% from the previous quarter
The company's return on assets fell by 8% QoQ
Dividends
What is AMRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AMRX.
Financial health
How did Amneal Pharmaceuticals financials performed over time
AMRX's total assets is 2.6% smaller than its total liabilities
The company's current ratio fell by 28% YoY but it rose by 3.8% QoQ
AMRX's quick ratio is down by 27% YoY but it is up by 2.7% from the previous quarter
Amneal Pharmaceuticals's equity has shrunk by 128% YoY and by 63% QoQ
The company's debt to equity rose by 40% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.